Why is this medication prescribed?

Darzalex Faspro (daratumumab and hyaluronidase-fihj) is a medication prescribed for the treatment of multiple myeloma, a type of cancer that affects plasma cells in the bone marrow. It is specifically used in combination with other medications to treat newly diagnosed or relapsed/refractory multiple myeloma in adults.

Darzalex Faspro works by targeting and binding to a protein called CD38, which is found on the surface of myeloma cells, leading to their destruction by the immune system.

How should this medicine be used?

Darzalex Faspro (daratumumab and hyaluronidase-fihj) is typically administered as an injection under the skin (subcutaneous injection). The specific dosage and administration schedule may vary depending on factors such as the patient’s weight, overall health, and the treatment plan prescribed by their healthcare provider. However, here is a general guideline on how Darzalex Faspro is commonly used:

• Preparation: The healthcare professional will prepare the medication according to the prescribed dosage.
• Injection Site: The injection is usually given into the abdomen (belly) or thigh. Your healthcare provider will advise you on the specific injection site.
• Administration: The injection is administered subcutaneously, meaning it is injected just beneath the skin. The healthcare provider will clean the injection site with an alcohol swab and then administer the injection.
• Frequency: Darzalex Faspro is typically administered once weekly for the first 6 weeks, then once every 2 weeks thereafter.
• Monitoring: Your healthcare team will monitor your response to the treatment and may adjust the dosage or administration schedule as needed based on your individual circumstances.
• Follow-Up: It’s essential to attend all scheduled appointments and follow up with your healthcare provider regularly to monitor your progress and address any concerns or side effects.

Always follow your healthcare provider’s instructions carefully regarding the dosage and administration of Darzalex Faspro. If you have any questions or concerns about how to use this medication, be sure to discuss them with your healthcare team.

Other uses for this medicine

Darzalex Faspro (daratumumab and hyaluronidase-fihj) is primarily used for the treatment of multiple myeloma, as mentioned earlier. However, it’s essential to note that healthcare providers may prescribe medications off-label, meaning for uses not specifically approved by regulatory agencies like the FDA. Off-label uses of Darzalex Faspro might include other types of cancer or conditions where CD38 is overexpressed, but such uses would be determined by the prescribing healthcare provider based on individual patient needs and clinical judgment.

What special precautions should I follow?

Regarding special precautions for Darzalex Faspro, here are some key points to consider:

• Hypersensitivity Reactions: Patients may experience hypersensitivity reactions to Darzalex Faspro, including severe infusion reactions and anaphylaxis. Healthcare providers typically administer premedications (such as antihistamines, corticosteroids, and acetaminophen) to help mitigate these reactions.
• Infections: Darzalex Faspro may increase the risk of infections, including respiratory tract infections and herpes zoster (shingles). Patients should be monitored for signs of infection, and appropriate treatment should be initiated promptly if an infection occurs.
• Interference with Blood Compatibility Testing: Darzalex Faspro may interfere with blood compatibility testing, particularly when using the indirect antiglobulin test (Coomb’s test) or other blood typing tests. This interference can persist for several months after treatment discontinuation.
• Neutropenia: Treatment with Darzalex Faspro may result in neutropenia (low white blood cell count), which can increase the risk of infections. Regular monitoring of blood cell counts is essential during treatment.
• Pregnancy and Breastfeeding: Darzalex Faspro may cause fetal harm if used during pregnancy. Pregnant women should be advised of the potential risks to the fetus, and effective contraception should be used during treatment and for at least three months after the last dose. It is not known whether Darzalex Faspro is excreted in human milk, so breastfeeding should be avoided during treatment and for at least three months after the last dose.
• Liver Toxicity: Darzalex Faspro may cause liver toxicity, including elevations in liver enzymes. Liver function tests should be performed regularly during treatment.

These are just some of the precautions associated with Darzalex Faspro. It’s crucial to discuss any concerns or questions with your healthcare provider before starting treatment. They can provide personalized guidance based on your medical history and individual circumstances.

What special dietary instructions should I follow?

As for special dietary instructions, there are no specific dietary restrictions associated with Darzalex Faspro. However, it’s essential to maintain a balanced diet and stay well-hydrated during treatment. If you have any dietary concerns or specific dietary needs, discuss them with your healthcare provider or a registered dietitian.

What should I do if I forget a dose?

If you forget a dose of Darzalex Faspro, contact your healthcare provider or treatment facility as soon as possible to determine the appropriate course of action. It may be necessary to reschedule the missed dose or adjust the treatment schedule based on your individual circumstances. Do not attempt to administer the missed dose yourself without consulting a healthcare professional.

What side effects can this medication cause?

Darzalex Faspro (daratumumab and hyaluronidase-fihj) can cause various side effects, which can vary in severity from person to person. Some common side effects include:

• Infusion Reactions: Symptoms may include fever, chills, nausea, vomiting, itching, rash, or difficulty breathing. These reactions typically occur during or shortly after the infusion and may require medical intervention.
• Infections: Darzalex Faspro can increase the risk of infections, such as respiratory tract infections, urinary tract infections, and herpes zoster (shingles).
• Neutropenia: A decrease in the number of neutrophils (a type of white blood cell) may occur, which can increase the risk of infections.
• Thrombocytopenia: A decrease in the number of platelets in the blood, which can lead to an increased risk of bleeding or bruising.
• Anemia: A decrease in red blood cell count, which can cause fatigue, weakness, and shortness of breath.
• Fatigue: Feelings of tiredness or exhaustion may occur as a result of the treatment.
• Nausea and Vomiting: Some patients may experience nausea and vomiting as side effects of Darzalex Faspro.
• Diarrhea: Changes in bowel habits, including diarrhea, may occur in some individuals.
• Peripheral Edema: Swelling in the extremities, such as the hands and feet, may occur as a side effect of the medication.
• Back Pain: Some patients may experience back pain as a side effect of Darzalex Faspro.

These are not all possible side effects of Darzalex Faspro. Other side effects may occur. It’s essential to report any new or worsening symptoms to your healthcare provider promptly. They can provide guidance on managing side effects and may adjust your treatment plan if necessary.

What should I know about storage and disposal of this medication?

Storage and disposal of Darzalex Faspro:

• Storage: Darzalex Faspro should be stored in the refrigerator at a temperature between 36°F to 46°F (2°C to 8°C). Do not freeze or shake the medication. Keep it in its original carton to protect it from light. If necessary, the medication can be stored at room temperature (up to 77°F or 25°C) for a single period of up to 30 days. Once removed from the refrigerator, it should not be returned.
• Disposal: Dispose of Darzalex Faspro needles, syringes, and other materials used to inject the medication in a puncture-resistant container as instructed by your healthcare provider or local regulations. Do not dispose of it in household trash or recycling bins. Follow any specific disposal instructions provided by your healthcare provider or pharmacist.

In case of emergency/overdose

In case of an emergency or overdose, such as experiencing severe infusion reactions or symptoms of toxicity, seek immediate medical attention by calling emergency services or visiting the nearest emergency room. Be sure to inform healthcare providers of the medication you have received and any relevant details about your condition.

What other information should I know?

• Inform all healthcare providers involved in your care that you are receiving Darzalex Faspro, including dentists and pharmacists, as it may interact with other medications or treatments.
• Keep a record of your injections, including the dates, doses, and any side effects experienced, to discuss with your healthcare provider during follow-up appointments.
• Attend all scheduled appointments for monitoring and follow-up with your healthcare provider, as regular monitoring is essential for the safe and effective use of Darzalex Faspro.
• Be aware of the potential for infusion reactions and other side effects, and report any new or worsening symptoms to your healthcare provider promptly.

By following these guidelines and staying informed about the proper storage, disposal, and emergency procedures related to Darzalex Faspro, you can help ensure the safe and effective use of the medication as part of your treatment plan.